WO2016025533A3 - Compositions and methods for treating synucleinopathies - Google Patents

Compositions and methods for treating synucleinopathies Download PDF

Info

Publication number
WO2016025533A3
WO2016025533A3 PCT/US2015/044736 US2015044736W WO2016025533A3 WO 2016025533 A3 WO2016025533 A3 WO 2016025533A3 US 2015044736 W US2015044736 W US 2015044736W WO 2016025533 A3 WO2016025533 A3 WO 2016025533A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
treating synucleinopathies
synucleinopathies
treating
Prior art date
Application number
PCT/US2015/044736
Other languages
French (fr)
Other versions
WO2016025533A2 (en
Inventor
Gabriela Caraveo PISO
Susan Lindquist
Luke J. Whitesell
Original Assignee
Whitehead Institute For Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute For Biomedical Research filed Critical Whitehead Institute For Biomedical Research
Publication of WO2016025533A2 publication Critical patent/WO2016025533A2/en
Publication of WO2016025533A3 publication Critical patent/WO2016025533A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid State Image Pick-Up Elements (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

In some aspects, described herein are methods of treating synucleinopathies using FK506.
PCT/US2015/044736 2014-08-11 2015-08-11 Compositions and methods for treating synucleinopathies WO2016025533A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462035991P 2014-08-11 2014-08-11
US62/035,991 2014-08-11

Publications (2)

Publication Number Publication Date
WO2016025533A2 WO2016025533A2 (en) 2016-02-18
WO2016025533A3 true WO2016025533A3 (en) 2016-04-14

Family

ID=55304754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/044736 WO2016025533A2 (en) 2014-08-11 2015-08-11 Compositions and methods for treating synucleinopathies

Country Status (1)

Country Link
WO (1) WO2016025533A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3506982A4 (en) * 2016-09-02 2020-07-22 The Johns Hopkins University Mif inhibitors and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207819A1 (en) * 2002-05-02 2003-11-06 Moskowitz Roland W. Compositions and methods for treating inflammatory connective tissue diseases
US20100086592A1 (en) * 2007-03-29 2010-04-08 Panacea Biotec Limited. Modified dosage forms of tacrolimus
US20110038851A1 (en) * 2007-05-16 2011-02-17 Michael Schlossmacher Treatment of synucleinopathies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207819A1 (en) * 2002-05-02 2003-11-06 Moskowitz Roland W. Compositions and methods for treating inflammatory connective tissue diseases
US20100086592A1 (en) * 2007-03-29 2010-04-08 Panacea Biotec Limited. Modified dosage forms of tacrolimus
US20110038851A1 (en) * 2007-05-16 2011-02-17 Michael Schlossmacher Treatment of synucleinopathies

Also Published As

Publication number Publication date
WO2016025533A2 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
EP3481434A4 (en) Crispr/cas9-based compositions and methods for treating retinal degenerations
EP3408344A4 (en) Well treatment methods and compositions
EP3261644A4 (en) Compositions and methods for treating retinal degradation
EP3538189A4 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
GB2561629B (en) Methods, Compositions and uses relating thereto
GB2560212B (en) Methods, compositions and uses relating thereto
GB2554485B (en) Methods, compositions and uses relating thereto
IL271728A (en) Agents, uses and methods for treatment
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
EP3186269A4 (en) Compositions, methods and kits for treating complement related disorders
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
EP3600291A4 (en) Compositions and methods for treating synucleinopathies
EP3107533A4 (en) Compositions and methods for treating neutropenia
EP3240533A4 (en) Compositions and methods for treating glaucoma
GB2577456B (en) Methods, compositions and uses relating thereto
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
GB2559645B (en) Methods, compositions and uses relating thereto
GB2560213C (en) Methods, compositions and uses relating thereto
GB201715799D0 (en) Methods, compositions and uses relating thereto
EP3389715A4 (en) Compositions and methods for treating cardiac dysfunction
WO2016025533A3 (en) Compositions and methods for treating synucleinopathies
WO2015191636A3 (en) Xanthine oxidase inhibitors and methods of use
GB201616676D0 (en) Methods, compositions and uses relating thereto
GB201616678D0 (en) Methods, compositions and uses relating thereto
GB201616645D0 (en) Methods, compositions and uses relating thereto

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15831501

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15831501

Country of ref document: EP

Kind code of ref document: A2